Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis

Rechallenge of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) after PD-1 blockade failure was an effective therapy for non-small cell lung cancer (NSCLC) patients with resistance to EGFR-TKIs. The third-generation TKIs, like osimertinib and furmonertinib, can reach higher co...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Chunfa, Zhang, Yuhai, Cheng, Wanwan, Zhang, Qingchao, Li, Mengzhen, Fang, Shencun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705570/
https://www.ncbi.nlm.nih.gov/pubmed/36457498
http://dx.doi.org/10.3389/fonc.2022.957661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705570/
https://www.ncbi.nlm.nih.gov/pubmed/36457498
http://dx.doi.org/10.3389/fonc.2022.957661

Ejemplares similares